Description:
A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis.
Start Date: October 24, 2024
Eligibility:
Ages 15 and above.
This study will enroll Male and Female participants.
Who has a defnite, probable or possible TB meningitis diagnosis with or without HIV co-infection.
Sample size is a total of 330 participant divided equally into 2 different treatment arms.
To Participate in the study kindly reach us via: